Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease
Valcarcel-Nazco C, Perestelo-Perez L, Molinuevo JL, Mar J, Castilla I, Serrano-Aguilar P

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
24916543

DOI
10.3233/JAD-132216

Indexing Status
Subject indexing assigned by NLM

MeSH
Alzheimer Disease /cerebrospinal fluid /complications /diagnosis /economics; Amyloid beta-Peptides /cerebrospinal fluid; Analysis of Variance; Biomarkers /cerebrospinal fluid; Cost-Benefit Analysis; Databases, Bibliographic /statistics & numerical data; Diagnosis, Differential; Female; Humans; Male; Mild Cognitive Impairment /etiology; Models, Statistical; Peptide Fragments /cerebrospinal fluid; Sensitivity and Specificity; tau Proteins /cerebrospinal fluid

AccessionNumber
22014038069

Date bibliographic record published
08/12/2014